Breast cancer break through as new vaccine shows 'promise' in treating aggressive form
Breast cancer patients have been given a new hope following the discovery of a ground breaking new vaccine which has sparked "promise" in battling an aggressive strain of the disease.
A clinical trial in the US involving women with triple-negative breast cancer saw them receive an experimental jab aimed at preventing tumour recurrence.The pioneering therapy, crafted by experts at Washington University School of Medicine in St.
Louis, is the first to publish results showing the potential of a neoantigen DNA vaccine in the fight against breast cancer, with the study appearing in Genome Medicine.The vaccine was praised for being "well-tolerated" and initiating significant immune reactions.
In the study, 18 participants faced with non-metastatic triple-negative breast cancer were given standard treatment along with three bespoke vaccine doses, each engineered to target specific tumour mutations and prime immune cells to destroy aberrant cells carrying those changes.
United States
|
Cases: 46 252 513
Deaths: 750 423
Recovered: 0
|
India
|
Cases: 34 321 025
Deaths: 459 652
Recovered: 0
|
Brazil
|
Cases: 21 835 785
Deaths: 608 235
Recovered: 0
|
United Kingdom
|
Cases: 9 215 683
Deaths: 141 607
Recovered: 0
|
Russia
|
Cases: 8 494 589
Deaths: 237 619
Recovered: 0
|